Hematology-Oncology Associates of the Quad-Cities, PC
Lung Cancer Trials
CTSU E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
CALGB 30605 A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer.
ACORN AC01L08: Randomized Phase 2b Study of Erbitux in Combnation with Platinum-based Chemotherapy as First Line Treatment of Recurrent or Advanced NSCLC.
CALGB 30704: Phase II Study of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the 2nd line Treatment of Advanced NSCLC.
CALGB 30607: Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer.
N0723 MARVEL: Marker Validation of Erlotinib in Lung Cancer - Phase III Biomarker Validation study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) randomized to Pemetrexed Versus Erlotinib.
CALGB 30605 A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer.
ACORN AC01L08: Randomized Phase 2b Study of Erbitux in Combnation with Platinum-based Chemotherapy as First Line Treatment of Recurrent or Advanced NSCLC.
CALGB 30704: Phase II Study of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the 2nd line Treatment of Advanced NSCLC.
CALGB 30607: Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer.
N0723 MARVEL: Marker Validation of Erlotinib in Lung Cancer - Phase III Biomarker Validation study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) randomized to Pemetrexed Versus Erlotinib.
